Basit öğe kaydını göster

dc.contributor.authorGUNEY-TEFEKLI, Esra
dc.contributor.authorURGANCIOGLU, Meri
dc.contributor.authorTugal-Tutkun, Ilknur
dc.date.accessioned2021-03-06T20:20:45Z
dc.date.available2021-03-06T20:20:45Z
dc.date.issued2006
dc.identifier.citationTugal-Tutkun I., GUNEY-TEFEKLI E., URGANCIOGLU M., "Results of interferon-alfa therapy in patients with Behcet uveitis", GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, cilt.244, ss.1692-1695, 2006
dc.identifier.issn0721-832X
dc.identifier.othervv_1032021
dc.identifier.otherav_f9d6d54b-a116-489d-8431-fca1080b4834
dc.identifier.urihttp://hdl.handle.net/20.500.12627/163609
dc.identifier.urihttps://doi.org/10.1007/s00417-006-0346-y
dc.description.abstractPurpose: To report on the results of interferon-alpha 2a (IFN alpha) treatment in patients with Behcet uveitis unresponsive to conventional immunosuppressive therapy. Methods: We retrospectively analyzed the medical records of 44 patients who had been treated with IFN alpha between September 2001 and May 2005. The initial dose of IFN alpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity. Results: Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4 +/- 10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2 +/- 13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6 +/- 1.2 to 0.8 +/- 0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFN alpha therapy (p < 0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients. Conclusions: A partial or complete response was obtained with IFN alpha therapy in 91% of Turkish patients with Behcet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFN alpha in different patient populations. Comparative studies are needed to investigate this hypothesis.
dc.language.isoeng
dc.subjectCerrahi Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectGöz Hastalıkları ve Cerrahisi
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectOFTALMOLOJİ
dc.titleResults of interferon-alfa therapy in patients with Behcet uveitis
dc.typeMakale
dc.relation.journalGRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume244
dc.identifier.issue12
dc.identifier.startpage1692
dc.identifier.endpage1695
dc.contributor.firstauthorID25189


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster